Cargando…

2823. In Vitro Efficacy of Minocycline on Clinical Gram Negative Bacterial Isolates

BACKGROUND: Urinary tract infections (UTIs) caused by multidrug-resistant Gram-negative bacilli (MDR-GNB) have become increasingly challenging to manage due to the limited number of available effective oral agents. Minocycline, a second-generation tetracycline with a broad antimicrobial spectrum and...

Descripción completa

Detalles Bibliográficos
Autores principales: Saleh, Omar M Abu, Crowley, Patrick, Ranganath, Nischal, Challener, Douglas, Streck, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677822/
http://dx.doi.org/10.1093/ofid/ofad500.2434
_version_ 1785150220732989440
author Saleh, Omar M Abu
Crowley, Patrick
Ranganath, Nischal
Challener, Douglas
Streck, Nicholas
author_facet Saleh, Omar M Abu
Crowley, Patrick
Ranganath, Nischal
Challener, Douglas
Streck, Nicholas
author_sort Saleh, Omar M Abu
collection PubMed
description BACKGROUND: Urinary tract infections (UTIs) caused by multidrug-resistant Gram-negative bacilli (MDR-GNB) have become increasingly challenging to manage due to the limited number of available effective oral agents. Minocycline, a second-generation tetracycline with a broad antimicrobial spectrum and reasonable urinary concentration, has recently gained attention as a potential treatment option for MDR-GNB UTIs. In this study, we aim to review the in vitro minocycline susceptibility against a wide spectrum of urinary GNB isolates performed at our reference lab. METHODS: We conducted a retrospective review of all minocycline susceptibility testing performed on urinary GNB isolates performed at the Mayo Clinic reference lab between 2013-2022. We stratified our results for different species based on phenotypic resistance profiles as well as known species-specific resistance association. RESULTS: During the study timeframe, we identified 28,388 GNB isolates that underwent minocycline susceptibility testing. Among the Escherichia coli (E.Coli) isolates resistant to ceftriaxone, ciprofloxacin, or meropenem, minocycline susceptibility was noted to be 78%, 46%, 76%, respectively (Fig 1). Among the Klebsiella pneumonia (KP) isolate resistant to ceftriaxone, ciprofloxacin, or meropenem, minocycline susceptibilities were 47%, 40%, and 53% respectively (Fig 1). Among the high risk Amp-C group Citrobacter freundii, Enterobacter Cloacae and Klebsiella aerogenes, minocycline susceptibility rate was noted to be 87%, 77%, and 89%, respectively (Fig 2). Finally, among the isolate group of non-fermenters including Achromobacter spp, Acinetobacter spp & Stenotrophomonas spp, susceptibility rates were noted to be 65%, 94%, and 100%, respectively (Fig 3). [Figure: see text] CONCLUSION: Minocycline showed in vitro activity against many hard to treat GNB urinary isolates, including ceftriaxone and meropenem resistant E.coli & KP isolates. High-risk Amp-C producing GN species & some of the less common GN including Stenotrophomonas, Acinetobacter, and Achromobacter. [Figure: see text] [Figure: see text] DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-10677822
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106778222023-11-27 2823. In Vitro Efficacy of Minocycline on Clinical Gram Negative Bacterial Isolates Saleh, Omar M Abu Crowley, Patrick Ranganath, Nischal Challener, Douglas Streck, Nicholas Open Forum Infect Dis Abstract BACKGROUND: Urinary tract infections (UTIs) caused by multidrug-resistant Gram-negative bacilli (MDR-GNB) have become increasingly challenging to manage due to the limited number of available effective oral agents. Minocycline, a second-generation tetracycline with a broad antimicrobial spectrum and reasonable urinary concentration, has recently gained attention as a potential treatment option for MDR-GNB UTIs. In this study, we aim to review the in vitro minocycline susceptibility against a wide spectrum of urinary GNB isolates performed at our reference lab. METHODS: We conducted a retrospective review of all minocycline susceptibility testing performed on urinary GNB isolates performed at the Mayo Clinic reference lab between 2013-2022. We stratified our results for different species based on phenotypic resistance profiles as well as known species-specific resistance association. RESULTS: During the study timeframe, we identified 28,388 GNB isolates that underwent minocycline susceptibility testing. Among the Escherichia coli (E.Coli) isolates resistant to ceftriaxone, ciprofloxacin, or meropenem, minocycline susceptibility was noted to be 78%, 46%, 76%, respectively (Fig 1). Among the Klebsiella pneumonia (KP) isolate resistant to ceftriaxone, ciprofloxacin, or meropenem, minocycline susceptibilities were 47%, 40%, and 53% respectively (Fig 1). Among the high risk Amp-C group Citrobacter freundii, Enterobacter Cloacae and Klebsiella aerogenes, minocycline susceptibility rate was noted to be 87%, 77%, and 89%, respectively (Fig 2). Finally, among the isolate group of non-fermenters including Achromobacter spp, Acinetobacter spp & Stenotrophomonas spp, susceptibility rates were noted to be 65%, 94%, and 100%, respectively (Fig 3). [Figure: see text] CONCLUSION: Minocycline showed in vitro activity against many hard to treat GNB urinary isolates, including ceftriaxone and meropenem resistant E.coli & KP isolates. High-risk Amp-C producing GN species & some of the less common GN including Stenotrophomonas, Acinetobacter, and Achromobacter. [Figure: see text] [Figure: see text] DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10677822/ http://dx.doi.org/10.1093/ofid/ofad500.2434 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Saleh, Omar M Abu
Crowley, Patrick
Ranganath, Nischal
Challener, Douglas
Streck, Nicholas
2823. In Vitro Efficacy of Minocycline on Clinical Gram Negative Bacterial Isolates
title 2823. In Vitro Efficacy of Minocycline on Clinical Gram Negative Bacterial Isolates
title_full 2823. In Vitro Efficacy of Minocycline on Clinical Gram Negative Bacterial Isolates
title_fullStr 2823. In Vitro Efficacy of Minocycline on Clinical Gram Negative Bacterial Isolates
title_full_unstemmed 2823. In Vitro Efficacy of Minocycline on Clinical Gram Negative Bacterial Isolates
title_short 2823. In Vitro Efficacy of Minocycline on Clinical Gram Negative Bacterial Isolates
title_sort 2823. in vitro efficacy of minocycline on clinical gram negative bacterial isolates
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677822/
http://dx.doi.org/10.1093/ofid/ofad500.2434
work_keys_str_mv AT salehomarmabu 2823invitroefficacyofminocyclineonclinicalgramnegativebacterialisolates
AT crowleypatrick 2823invitroefficacyofminocyclineonclinicalgramnegativebacterialisolates
AT ranganathnischal 2823invitroefficacyofminocyclineonclinicalgramnegativebacterialisolates
AT challenerdouglas 2823invitroefficacyofminocyclineonclinicalgramnegativebacterialisolates
AT strecknicholas 2823invitroefficacyofminocyclineonclinicalgramnegativebacterialisolates